A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
SELVITA operates in the Medical - Diagnostics & Research industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Revenue | 92M | 92M | 80M | 35M |
| Net Income | 6.8M | 6.8M | 3.8M | 5.1M |
| EPS | $0.38 | $0.38 | $0.21 | $0.27 |
| Free Cash Flow | 17M | 17M | 22M | 7.5M |
| ROIC | 19.0% | 13.2% | 14.2% | 17.0% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | 0.48 | 0.47 | 0.22 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | 10M | 10M | 6.7M | 5.0M |
| Operating Margin | 11.0% | 11.0% | 8.4% | 14.2% |
| ROE | 11.6% | 12.4% | 8.5% | 13.0% |
| Shares Outstanding | 18M | 18M | 19M | 19M |
| Metric | 2020 | 2021 | 2022 | TTM |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 35M | 80M | 92M | 92M |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | 5.0M | 6.7M | 10M | 10M |
| Op. Margin | 14.2% | 8.4% | 11.0% | 11.0% |
| Net Income | 5.1M | 3.8M | 6.8M | 6.8M |
| Net Margin | 14.5% | 4.8% | 7.4% | 7.4% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | 17.0% | 14.2% | 13.2% | 19.0% |
| ROE | 13.0% | 8.5% | 12.4% | 11.6% |
| ROA | 9.1% | 4.4% | 5.5% | 5.2% |
| Cash Flow | ||||
| Op. Cash Flow | 7.5M | 22M | 17M | 17M |
| Free Cash Flow | 7.5M | 22M | 17M | 17M |
| Owner Earnings | 4.1M | 15M | 8.7M | 8.7M |
| CapEx | 0 | 0 | 0 | 0 |
| Maint. CapEx | 3.5M | 7.1M | 8.3M | 8.3M |
| Growth CapEx | N/A | N/A | N/A | 0 |
| D&A | 3.5M | 7.1M | 8.3M | 8.3M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A |
| Debt Repayment | 2K | 2.4M | 2.5M | 2.5M |
| Balance Sheet | ||||
| Net Debt | -15M | 2.2M | 12M | -17M |
| Cash & Equiv. | 24M | 22M | 17M | 17M |
| Long-Term Debt | N/A | 21M | 25M | 25M |
| Debt/Equity | 0.22 | 0.47 | 0.48 | 0.00 |
| Interest Coverage | 27.8 | 5.2 | 9.8 | 9.8 |
| Equity | 39M | 51M | 59M | 59M |
| Total Assets | 56M | 118M | 131M | 131M |
| Total Liabilities | 17M | 65M | 70M | 70M |
| Intangibles | N/A | 9.6M | 7.8M | 7.8M |
| Retained Earnings | 1.4M | N/A | N/A | N/A |
| Working Capital | 28M | 21M | 18M | 18M |
| Current Assets | 37M | 46M | 46M | 46M |
| Current Liabilities | 8.4M | 25M | 28M | 28M |
| Per Share Data | ||||
| EPS | 0.27 | 0.21 | 0.38 | 0.38 |
| Owner EPS | 0.21 | 0.80 | 0.49 | 0.49 |
| Book Value | 2.06 | 2.73 | 3.31 | 3.31 |
| Cash Flow/Share | 0.40 | 1.18 | 0.95 | 0.85 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 19.0M | 18.6M | 17.8M | 17.8M |
| Valuation | ||||
| P/E Ratio | 45.0 | 95.6 | 48.7 | 85.0 |
| P/FCF | 30.5 | 16.7 | 19.6 | 34.2 |
| EV/EBIT | 42.8 | 54.9 | 34.1 | 55.9 |
| Price/Book | 5.9 | 7.2 | 5.6 | 9.8 |
| Price/Sales | 6.5 | 4.6 | 3.6 | 6.3 |
| FCF Yield | 3.3% | 6.0% | 5.1% | 2.9% |
| Market Cap | 230M | 367M | 332M | 579M |
| Avg. Price | 10.19 | 18.60 | 17.30 | 32.50 |
| Year-End Price | 12.09 | 19.73 | 18.62 | 32.50 |
SELVITA passes 4 of 9 quality checks, suggesting mixed fundamentals.
SELVITA trades at 85.0x trailing earnings, compared to its 15-year median P/E of 48.7x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 34.2x vs a median of 19.6x. The company's 5-year average ROIC is 14.8%. At current prices, the estimated annualized return to fair value is +17.9%.
SELVITA (SLV-WA) has a current P/E ratio of 85.0, compared to its historical median P/E of 48.7. The stock is currently considered Expensive based on its historical valuation range.
SELVITA (SLV-WA) has a 5-year average return on invested capital (ROIC) of 14.8%. This indicates solid capital allocation.
SELVITA (SLV-WA) has a market capitalization of $579M. It is classified as a small-cap stock.
SELVITA (SLV-WA) does not currently pay a regular dividend.
Based on historical P/E analysis, SELVITA (SLV-WA) appears expensive. The current P/E of 85.0 is 75% above its historical median of 48.7. The estimated fair value CAGR (P/E method) is 7.5%.
SELVITA (SLV-WA) operates in the Medical - Diagnostics & Research industry, within the Healthcare sector.
SELVITA (SLV-WA) reported annual revenue of $92 million in its most recent fiscal year, based on SEC EDGAR filings.
SELVITA (SLV-WA) has a net profit margin of 7.4%. This is a modest margin.
SELVITA (SLV-WA) generated $17 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
SELVITA (SLV-WA) has a debt-to-equity ratio of 0.48. This indicates a conservatively financed balance sheet.
SELVITA (SLV-WA) reported earnings per share (EPS) of $0.38 in its most recent fiscal year.
SELVITA (SLV-WA) has a return on equity (ROE) of 12.4%. This indicates moderate shareholder returns.
The Ledger Terminal provides 3 years of financial data for SELVITA (SLV-WA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SELVITA (SLV-WA) has a book value per share of $3.31, based on its most recent annual SEC filing.
No recent press releases.